Clinical Trial Update: A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating novel scheduling of cabazitaxel for metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)

Snippet

Sponsor: Jeffrey Yachnin M.D., PhD. | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 2 | Status: COMPLETED